Related references
Note: Only part of the references are listed.Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines
Michelle P. Aranha et al.
JOURNAL OF IMMUNOLOGY (2021)
Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein?derived peptides
Michelle P. Aranha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study
Elodie Pastural et al.
VACCINE (2020)
Update on group A streptococcal vaccine development
James B. Dale et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2020)
Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease
Philip M. Giffard et al.
PLOS NEGLECTED TROPICAL DISEASES (2019)
The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics
Johan Vekemans et al.
CLINICAL INFECTIOUS DISEASES (2019)
Structure-based design of broadly protective group a streptococcal M protein-based vaccines
James B. Dale et al.
VACCINE (2017)
A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development
Martina Sanderson-Smith et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Potential coverage of a multivalent M protein-based group A streptococcal vaccine
James B. Dale et al.
VACCINE (2013)
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
James B. Dale et al.
VACCINE (2011)
Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes
Thomas A. Penfound et al.
VACCINE (2010)
Global emm type distribution of group A streptococci: systematic review and implications for vaccine development
Andrew C. Steer et al.
LANCET INFECTIOUS DISEASES (2009)
The global burden of group A streptococcal diseases
JR Carapetis et al.
LANCET INFECTIOUS DISEASES (2005)
Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers
SA McNeil et al.
CLINICAL INFECTIOUS DISEASES (2005)
Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections
MA Hall et al.
INFECTION AND IMMUNITY (2004)
An HMM model for coiled-coil domains and a comparison with PSSM-based predictions
M Delorenzi et al.
BIOINFORMATICS (2002)
Share Paper
